HRP20140102T1 - Cjepivo za prevenciju relapsa raka dojke - Google Patents
Cjepivo za prevenciju relapsa raka dojke Download PDFInfo
- Publication number
- HRP20140102T1 HRP20140102T1 HRP20140102AT HRP20140102T HRP20140102T1 HR P20140102 T1 HRP20140102 T1 HR P20140102T1 HR P20140102A T HRP20140102A T HR P20140102AT HR P20140102 T HRP20140102 T HR P20140102T HR P20140102 T1 HRP20140102 T1 HR P20140102T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- preparation according
- formulated
- human
- injection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/38—Antigens from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (19)
1. Pripravak koji sadrži farmaceutski učinkovit nosač i peptid koji sadrži sekvencu amino kiseline SF.Q ID NO: 2 za uporabu za poticanje zaštitnog ili terapijskog imuniteta protiv ponovnog nastanka raka dojke kod subjekta, naznačen time da subjekt ima imunohistokemijsku (IHC) ocjenu od 1+ ili 2+ za ekspresiju HER2/neu proteina i ocjenu fluorescencije na mjestu hibridizacije (FISH) od manje od 2.0 ± 20% za ekspresiju HER2/neu gena.
2. Pripravak prema zahtjevu 1, naznačen time je pripravak formuliran da se daje mjesečno putem inokulacije ili injekcije, poželjno pomoću intradermalne injekcije, dok se uspostavi zaštitni imunitet.
3. Pripravak prema zahtjevu 2, naznačen time da je pripravak formuliran da se daje kao tri do šest mjesečnih injekcija, te poželjno kao šest mjesečnih injekcija.
4. Pripravak prema bilo kojem zahtjevu od 1 do 3, naznačen time da je pripravak formuliran da se daje sa pripravkom booster cjepiva, pri čemu pripravak booster cjepiva sadrži farmaceutski učinkovit nosač i peptid koji sadrži sekvencu amino kiseline SEQ ID N():2.
5. Pripravak prema bilo kojem zahtjevu od 1 do 4, naznačen time da je booster pripravak formuliran za davanje putem inokulacije ili injekcije, poželjno pomoću intradermalne injekcije.
6. Pripravak prema bilo kojem zahtjevu od 1 do 5, naznačen time da je pripravak formuliran za inokulaciju ili injekciju u jednoj ili više podijeljenih doza i/ili booster pripravak je formuliran za inokulaciju ili injekciju u jednoj ili više odvojenih doza.
7. Pripravak prema zahtjevu 6, naznačen time da dvije doze pripravka i/ili dvije doze booster pripravka sadrže jednake koncentracije peptida.
8. Pripravak prema zahtjevima 6 ili 7, naznačen time da su mjesta za inokulaciju ili injekciju na tijelu smještena na udaljenosti najmanje 5 cm jedno od drugoga.
9. Pripravak prema bilo kojem zahtjevu od 4 do 8, naznačen time da je booster pripravak formuliran da se daje svakih 6 do 12 mjeseci, poželjno svakih šest mjeseci, nakon završetka primarne intimizacije.
10. Pripravak prema bilo kojem zahtjevu od 1 do 9. naznačen time subjekt je čovjek.
11. Pripravak prema zahtjevu 10, naznačen time da čovjek eksprimira humani leukocitni antigen A2 ili humani leukocitni antigen A3.
12. Pripravak prema bilo kojem zahtjevu od 1 do 11, naznačen time da je subjekt u potpunoj kliničkoj remisiji nakon dijagnoze pozitivnog čvora ili negativnog čvora raka dojke, ili pri čemu je subjekt u djelomičnoj remisiji raka dojke.
13. Pripravak prema bilo kojem zahtjevu od 1 do 12, naznačen time da pripravak dodatno sadrži adjuvant, pri čemu je adjuvant poželjno rekombinantni humani stimulirajući faktor kolonije granulocita/makrofaga.
14. Pripravak prema bilo kojem zahtjevu od 4 do 13, naznačen time da pripravak booster cjepiva dodatno sadrži adjuvant, pri čemu je adjuvant poželjno rekombinantni humani stimulirajući faktor kolonije granulocita/makrofaga.
15. Pripravak prema bilo kojem zahtjevu od 1 do 14, naznačen time da pripravak inducira citotoksični T limfocitni odgovor na peptid koji sadrži sekvencu amino kiseline SEQ ID NO:2.
16. Pripravak prema bilo kojem zahtjevu od 10 do 15. naznačen time da je čovjek imao rak dojke sa pozitivnim čvorom, ili pri čemu je čovjek imao rak dojke sa negativnim čvorom.
17. Pripravak prema bilo kojem zahtjevu od 1 do 16, naznačen time da pripravak sadrži
(i) 0.1 mg do 10 mg peptida, poželjno 0.1. 0.5 ili 1 mg peptida; te
(ii) kao adjuvant 0.01 do 0.5 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF), a poželjno 0.25 ili 0.125 mg GM-CSF.
18. Pripravak prema zahtjevu 1, za uporabu kod subjekta koji je čovjek koji ima imunohistokemijsku (IHC) ocjenu 1+ ili 2+ za ekspresiju HER2/neu proteina i ocjenu fluorescencije na mjestu hibridizacije (FISH) od manje od 2.0 ± 20% za ekspresiju HER2/neu gena, naznačen time da pripravak sadrži,
(i) pripravak cjepiva koji sadrži 1 mg peptida koji sadrži sekvencu amino kiseline SHQ ID. NO:2, i 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak cjepiva formuliran za davanje kao tri do šest mjesečnih injekcija, poželjno kao intradermalne injekcije; te
(ii) pripravak booster cjepiva koji sadrži 1 mg peptida koji sadrži sekvencu amino kiseline SEQ ID NO:2, i 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak booster cjepiva formuliran za davanje pomoću injekcije, poželjno intradermalne injekcije, svakih šest mjeseci nakon završetka primarne imunizacije.
19. Pripravak prema bilo kojem zahtjevu od 1 do 18, naznačen time da subjekt ima imunohistokemijsku (IHC) ocjenu od 1+ za ekspresiju HER2/neu proteina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94152407P | 2007-06-01 | 2007-06-01 | |
| PCT/US2008/060044 WO2008150577A1 (en) | 2007-06-01 | 2008-04-11 | Vaccine for the prevention of breast cancer relapse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140102T1 true HRP20140102T1 (hr) | 2014-03-28 |
Family
ID=40094045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140102AT HRP20140102T1 (hr) | 2007-06-01 | 2008-04-11 | Cjepivo za prevenciju relapsa raka dojke |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8222214B2 (hr) |
| EP (2) | EP2722336A1 (hr) |
| JP (6) | JP5635399B2 (hr) |
| KR (5) | KR101572474B1 (hr) |
| CN (2) | CN105816867A (hr) |
| AU (1) | AU2008260399C1 (hr) |
| CA (1) | CA2687368C (hr) |
| CY (1) | CY1114912T1 (hr) |
| DK (1) | DK2162149T3 (hr) |
| ES (1) | ES2445399T3 (hr) |
| HR (1) | HRP20140102T1 (hr) |
| MX (1) | MX2009012858A (hr) |
| PL (1) | PL2162149T3 (hr) |
| PT (1) | PT2162149E (hr) |
| SI (1) | SI2162149T1 (hr) |
| WO (1) | WO2008150577A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| HRP20140102T1 (hr) * | 2007-06-01 | 2014-03-28 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Cjepivo za prevenciju relapsa raka dojke |
| KR20170097234A (ko) | 2008-12-10 | 2017-08-25 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유방암 재발 예방용 백신 |
| CN104271591B (zh) | 2012-02-17 | 2017-09-26 | 梅约医学教育与研究基金会 | 用于生成能够识别表达HER2/neu多肽的癌细胞的CD8+T细胞的方法和材料 |
| WO2013169538A1 (en) | 2012-05-08 | 2013-11-14 | Albert Einstein College Of Medicine Of Yeshiva University | Nanoparticle delivery vehicle for s-nitroso-n-acetyl cysteine and uses thereof |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| CA2840997A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
| CN103961700A (zh) * | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | 粘膜给予用疫苗组合物 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| CN104513293A (zh) * | 2013-09-26 | 2015-04-15 | 深圳信立泰药业股份有限公司 | 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 |
| WO2015066020A1 (en) * | 2013-10-28 | 2015-05-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of monitoring immune responses |
| US10434152B2 (en) * | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| WO2017132562A1 (en) | 2016-01-29 | 2017-08-03 | Heyue Zhou | Antigen binding proteins that bind pd-l1 |
| EP3463438B1 (en) | 2016-05-31 | 2022-04-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine therapy for treatment of endometrial and ovarian cancer |
| US11564987B2 (en) | 2018-10-21 | 2023-01-31 | Slsg Limited Llc | Combination immunotherapy for treatment of triple-negative breast cancer |
| US20240183856A1 (en) | 2021-05-04 | 2024-06-06 | Aston Sci. Inc. | Her2 vaccine composition |
| KR20230017640A (ko) | 2021-07-28 | 2023-02-06 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| DE69031120T2 (de) * | 1989-05-19 | 1998-01-15 | Genentech, Inc., South San Francisco, Calif. | Her2 extrazellulare domäne |
| US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| WO1996018409A1 (en) * | 1994-12-14 | 1996-06-20 | The Scripps Research Institute | In vivo activation of tumor-specific cytotoxic t cells |
| US6514942B1 (en) * | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| US20030022820A1 (en) * | 1995-12-14 | 2003-01-30 | Linda A. Sherman | In vivo activation of tumor-specific cytotoxic t cells |
| US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| EP1246597B1 (en) * | 1999-08-03 | 2015-01-14 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| AU7743100A (en) | 1999-09-30 | 2001-04-30 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| US6602510B1 (en) * | 2000-04-05 | 2003-08-05 | Epimmune Inc. | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20030224036A1 (en) * | 1999-12-13 | 2003-12-04 | Fikes John D | Hla class I a2 tumor associated antigen peptides and vaccine compositions |
| US20070098776A1 (en) * | 1999-12-13 | 2007-05-03 | Fikes John D | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20040121946A9 (en) * | 2000-12-11 | 2004-06-24 | John Fikes | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| WO2003004609A2 (en) * | 2001-07-03 | 2003-01-16 | Lexicon Genetics Incorporated | Novel human kielin-like proteins and polynucleotides encoding the same |
| WO2003005952A2 (en) * | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| US20030049253A1 (en) * | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| US8802618B2 (en) | 2002-03-08 | 2014-08-12 | Board Of Regents, The University Of Texas System | Controlled modulation of amino acid side chain length of peptide antigens |
| KR100555211B1 (ko) * | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신 |
| EP1553966B1 (en) * | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| WO2004069866A1 (en) * | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
| WO2005046571A2 (en) * | 2003-06-06 | 2005-05-26 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005014634A1 (en) | 2003-08-12 | 2005-02-17 | Agt Biosciences Limited | A gene and uses therefor |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| US20060275777A1 (en) * | 2005-06-03 | 2006-12-07 | Waelti Ernst R | Novel strategies for protein vaccines |
| HRP20140102T1 (hr) * | 2007-06-01 | 2014-03-28 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Cjepivo za prevenciju relapsa raka dojke |
-
2008
- 2008-04-11 HR HRP20140102AT patent/HRP20140102T1/hr unknown
- 2008-04-11 EP EP13191663.7A patent/EP2722336A1/en not_active Ceased
- 2008-04-11 MX MX2009012858A patent/MX2009012858A/es active IP Right Grant
- 2008-04-11 CA CA2687368A patent/CA2687368C/en active Active
- 2008-04-11 EP EP08745615.8A patent/EP2162149B1/en active Active
- 2008-04-11 ES ES08745615.8T patent/ES2445399T3/es active Active
- 2008-04-11 KR KR1020097027587A patent/KR101572474B1/ko not_active Expired - Fee Related
- 2008-04-11 KR KR1020207004398A patent/KR102283639B1/ko not_active Expired - Fee Related
- 2008-04-11 AU AU2008260399A patent/AU2008260399C1/en not_active Ceased
- 2008-04-11 CN CN201610201242.6A patent/CN105816867A/zh active Pending
- 2008-04-11 CN CN200880018401A patent/CN101678093A/zh active Pending
- 2008-04-11 KR KR1020187014920A patent/KR102079921B1/ko not_active Expired - Fee Related
- 2008-04-11 KR KR1020217023573A patent/KR20210097209A/ko not_active Abandoned
- 2008-04-11 WO PCT/US2008/060044 patent/WO2008150577A1/en not_active Ceased
- 2008-04-11 US US12/602,214 patent/US8222214B2/en not_active Expired - Fee Related
- 2008-04-11 JP JP2010510385A patent/JP5635399B2/ja not_active Expired - Fee Related
- 2008-04-11 KR KR1020157007937A patent/KR101863534B1/ko not_active Expired - Fee Related
- 2008-04-11 PL PL08745615T patent/PL2162149T3/pl unknown
- 2008-04-11 DK DK08745615.8T patent/DK2162149T3/da active
- 2008-04-11 SI SI200831143T patent/SI2162149T1/sl unknown
- 2008-04-11 PT PT87456158T patent/PT2162149E/pt unknown
-
2012
- 2012-06-27 US US13/534,550 patent/US8796220B2/en active Active
-
2014
- 2014-01-30 CY CY20141100076T patent/CY1114912T1/el unknown
- 2014-07-04 JP JP2014138567A patent/JP6097724B2/ja not_active Expired - Fee Related
- 2014-07-09 US US14/327,224 patent/US9370560B2/en not_active Expired - Fee Related
-
2016
- 2016-10-28 JP JP2016211150A patent/JP2017071607A/ja active Pending
-
2018
- 2018-03-05 US US15/912,156 patent/US10842856B2/en not_active Expired - Fee Related
- 2018-08-16 JP JP2018153050A patent/JP7072467B2/ja not_active Expired - Fee Related
-
2020
- 2020-09-25 JP JP2020161232A patent/JP2021001218A/ja active Pending
- 2020-10-21 US US17/076,635 patent/US20220347281A1/en not_active Abandoned
-
2022
- 2022-01-12 US US17/574,178 patent/US20220241389A1/en not_active Abandoned
- 2022-04-18 JP JP2022068170A patent/JP2022095926A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140102T1 (hr) | Cjepivo za prevenciju relapsa raka dojke | |
| JP2010529026A5 (hr) | ||
| RU2435782C2 (ru) | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция | |
| TW575574B (en) | Cyclic boroproline compounds | |
| ME02317B (me) | Neuroprotekcija kod demijelinizacijskih bolesti | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| JPH07504683A (ja) | Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用 | |
| CN104338132A (zh) | 一种病毒免疫治疗药物复合物及其用途 | |
| JP2005526085A5 (hr) | ||
| RU2015106742A (ru) | Композиции, содержащие химерные молекулы ospa и способы их применения | |
| Shiohara et al. | Pathomechanisms of lichen planus autoimmunity elicited by cross-reactive T cells | |
| del Carmen Domínguez et al. | Biodistribution and pharmacokinetic profiles of an altered peptide ligand derived from heat-shock proteins 60 in Lewis rats | |
| ES2647584T3 (es) | Método para producir vacunas que comprende la irradiación de microorganismos en una composición que comprende aminoácidos y ortofosfato de manganeso | |
| Kim et al. | Dectin-1 signaling coordinates innate and adaptive immunity for potent host defense against viral infection | |
| FI3733712T3 (fi) | Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä | |
| CN106456728A (zh) | 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法 | |
| Zhang et al. | Modulation by glycyrrhizin of the cell-surface expression of H-2 class I antigens on murine tumour cell lines and normal cell populations | |
| Kataoka et al. | Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors | |
| JP2013506682A5 (hr) | ||
| CN101838306A (zh) | 一种k4多肽合成产物及其应用 | |
| CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
| ES2327432T3 (es) | Vacunas contra el vhc para pacientes con vhc cronica. | |
| Feng et al. | Isolation and potential immunological characterization of TPSGLVY, a novel bursal septpeptide isolated from the bursa of Fabricius | |
| JP2022513438A5 (hr) | ||
| ES2338773T3 (es) | Peptidos modificados y su uso para el tratamiento de enfermedades autoinmunitarias. |